Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Last trade$1.06
Day change-$0.005 (-0.47%)
Day range$1.01 – $1.12
Volume691,370
Market cap$116M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$116.17M
Price / earnings
—
Price / book
2.27×
Price / sales
1.32×
EV / sales
1.45×
EV / EBITDA
-16.54×
Profitability
Earnings per share
-$0.18
Return on assets
-13.34%
Return on equity
-37.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.81×
Current ratio
2.81×
Quick ratio
2.75×
Cash ratio
0.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CDXS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$19.26M
$14.92M
$15.25M
$38.92M
$8.6M
$15.33M
$7.54M
$21.46M
Cost of revenue
$4.01M
$3.51M
$2.06M
$2.04M
$2.47M
$2.1M
$2.73M
$3.65M
Gross profit
$15.25M
$11.4M
$13.18M
$36.87M
$6.14M
$13.23M
$4.81M
$17.81M
Selling, general and administrative
$10.1M
$10.93M
$9.78M
$11.19M
$11.22M
$12.32M
$12.36M
$13.05M
Research and development
$12.59M
$11.71M
$11.45M
$11.72M
$13.87M
$13.78M
$12.94M
$12.1M
Total operating expenses
$22.68M
$22.63M
$21.23M
$26.31M
$25.09M
$26.09M
$25.3M
$25.15M
Operating income
-$7.44M
-$11.23M
-$8.04M
$10.56M
-$18.95M
-$12.86M
-$20.49M
-$7.34M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$8.12M
-$12M
-$8.67M
$9.62M
-$19.61M
-$13.26M
-$20.68M
-$10.37M
Income taxes
$9K
$10K
$36K
$18K
$8K
$10K
$11K
$3K
Net income
-$8.13M
-$12.01M
-$8.7M
$9.6M
-$19.62M
-$13.27M
-$20.69M
-$10.38M
Net income attributable to common shareholders
-$8.13M
-$12.01M
-$8.7M
$9.6M
-$19.62M
-$13.27M
-$20.69M
-$10.38M
EBITDA
-$6.3M
-$10.02M
-$6.76M
$15.32M
-$17.59M
-$11.52M
-$19.29M
-$6.13M
Basic earnings per share
-$0.08
-$0.13
-$0.10
$0.11
-$0.22
-$0.16
-$0.25
-$0.13
Diluted earnings per share
-$0.08
-$0.13
-$0.10
$0.11
-$0.22
-$0.16
-$0.25
-$0.13
Recent news
Company coverage with links to the original publishers.
Codexis (CDXS) reported a quarterly loss of $0.08 per share, beating consensus estimates of $0.09 loss, with revenues of $19.26 million exceeding expectations by 4.16%. Despite the earnings beat and consistent outperformance over four quarters, the stock has declined 40.1% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Opus Genetics reported a quarterly loss of $0.18 per share, missing the consensus estimate of $0.14 by 28.57%, and posted revenues of $1.14 million, falling 43.8% short of expectations. The company has underperformed consensus estimates in 3 of the last 4 quarters. Despite a 109% year-to-date gain, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Codexis, Inc. announced a $60 million senior secured term loan agreement with Trinity Capital Inc. to refinance existing debt and provide capital flexibility for advancing its ECO Synthesis Manufacturing Platform for siRNA therapeutic manufacturing. The new facility offers 48 months of interest-only payments followed by a 12-month amortization period beginning November 2030, with post-closing outstanding debt of $42.5 million.
Codexis presented data at TIDES Europe 2026 demonstrating its ECO Synthesis Manufacturing Platform achieved over 90% product quality at 100-gram scale while nearly halving cycle time. The company also showcased new capabilities in tissue-targeting functionality and biological evidence that defined siRNA stereochemistry produced 3-4 fold increased potency compared to traditional chemical synthesis methods, advancing the platform toward industrialization and adoption readiness.
Arcturus Therapeutics (ARCT) reported a quarterly loss of $0.26 per share, beating consensus estimates of $0.60 loss by 56.67%, with revenues of $18.3 million exceeding estimates by 116.10%. The stock has gained 77.3% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.